Merck: EU approves Keytruda for lung cancer
(CercleFinance.com) - The European Commission has approved Merck's Keytruda for patients with metastatic nonsquamous non-small cell lung cancer, the U.
S. drugmaker said on Monday.
The EU executive arm has approved the anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adults whose tumors have no EGFR or ALK positive mutations, Merck said.
Brussels' approval was based on results from a pivotal phase 3 trial showing that Keytruda with pemetrexed and chemotherapy significantly improved overall survival and progression-free survival compared with chemotherapy alone, it added.
The approval allows marketing of the combination in all 28 EU member states plus Iceland, Lichtenstein and Norway.
Merck shares are currently up 0.9% in Wall Street.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
S. drugmaker said on Monday.
The EU executive arm has approved the anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adults whose tumors have no EGFR or ALK positive mutations, Merck said.
Brussels' approval was based on results from a pivotal phase 3 trial showing that Keytruda with pemetrexed and chemotherapy significantly improved overall survival and progression-free survival compared with chemotherapy alone, it added.
The approval allows marketing of the combination in all 28 EU member states plus Iceland, Lichtenstein and Norway.
Merck shares are currently up 0.9% in Wall Street.
Copyright (c) 2018 CercleFinance.com. All rights reserved.